摘要
目的 设计特异性耐受原 ,通过其鼻黏膜耐受治疗对实验性自身免疫性重症肌无力 (EAMG)发病过程的影响 ,以探讨该疗法在模型应用中的可行性。方法 用 Lewis大鼠建立 EAMG模型 ,选取双类似物作为耐受原在致敏同时给予鼻黏膜耐受治疗 ,动态观察大鼠体重及临床评分改变。结果 虽然治疗组大鼠发病率不降低 ,但是在 EAMG急性期和慢性期 ,其临床症状均较对照组减轻 (P <0 .0 5 )。结论 用双类似物鼻黏膜耐受可以达到治疗 EAMG的目的 ,其结果为抗原特异性治疗重症肌无力 (MG)和其他自身免疫性疾病 (AID)提供了依据。
Objective To verify the feasibility of nasal tolerance on experimental autoimmune myasthenia gravis (EAMG) by observing the clinical process in EAMG rats treated with dual analogue.Methods 300 g/rat of dual analogues was given to Lewis rats immunized with acetylcholine receptor (AChR) in complete Freund's adjuvant (CFA) during the time of immunization while the weights and clinical symptoms were evaluated.Results Although the incidence of treated group was unchangeable, the clinical symptoms were relieved in both acute and chronic phrase(P <0 05).Conclusions It's possible to utilize the immunological nasal tolerance to treat EAMG. This throws light to mucosal administration of dual analogue as an alternative maneuver in human myasthenia gravis (MG) as well as other autoimmune diseases.
出处
《中国神经免疫学和神经病学杂志》
CAS
2002年第4期206-209,共4页
Chinese Journal of Neuroimmunology and Neurology
基金
国家自然科学基金资助项目 (3 9970 2 62 )
